Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) entered into a settlement agreement with Teva Pharmaceuticals Industries Ltd ...
Zacks.com on MSN23h
Catalyst (CPRX) Soars 16.7%: Is Further Upside Left in the Stock?Catalyst (CPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...
Despite weathering significant criticism from lawmakers and patient groups over the steep cost of its rare disease med ...
Stephens has recently initiated Catalyst Pharmaceuticals Inc (CPRX) stock to Overweight rating, as announced on November 18, 2024, according to Finviz. Earlier, on March 14, 2024, Citigroup had ...
Johnson & Johnson received Priority Review of nipocalimab in generalized myasthenia gravis. GSK’s B7-H3-targeted ...
Catalyst Pharmaceuticals, Inc. has announced a settlement agreement with Teva Pharmaceuticals, resolving the patent ...
Catalyst Rises as Q2 Earnings & Revenues Beat Estimates Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) reported adjusted earnings of 56 cents per share for the second quarter of 2024, beating the ...
Innovaccer has raised a $275M Series F from investors including B Capital Group, Banner Health, Danaher Ventures, Generation ...
Professor Douglas Boateng, Board Chairman of the Minerals Income Investment Fund (MIIF), has underscored the potential of ...
We recently published a list of 10 Best Blue Chip Stocks to Buy for 2025. In this article, we are going to take a look at ...
Hosted on MSN12h
Lipozem: We Tested It (Update 2025)—Here’s Our Honest Lipozem Review After 113 Days!Maintaining a healthy body weight is essential for overall well-being, and many people are actively seeking natural solutions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback